Stockscreener 앱 받기
6.50
0.00%
0.00
시간 외 거래:
6.57
0.07
+1.08%
전일 마감가:
$6.50
열려 있는:
$6.43
하루 거래량:
206.63K
Relative Volume:
0.73
시가총액:
$144.45M
수익:
-
순이익/손실:
$-52.07M
주가수익비율:
-31.30
EPS:
-0.2077
순현금흐름:
$-44.93M
1주 성능:
-5.39%
1개월 성능:
+14.24%
6개월 성능:
-35.96%
1년 성능:
-51.13%
1일 변동 폭
$6.25
$6.50
1주일 범위
$6.25
$7.1099
52주 변동 폭
$4.81
$14.44
Cybin Inc Stock (CYBN) Company Profile
명칭
Cybin Inc
전화
908 764 8385
주소
100 King Street West, Suite 5600, Toronto
CYBN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
6.50 | 144.45M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Cybin Inc 주식(CYBN)의 최신 뉴스
Psychedelic drug developer Cybin partners with Osmind - MSN
Cybin (CYBN) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Participate at the 28th Annual Milken Institute Global Conference | CYBN Stock News - GuruFocus
Cybin to Participate at the 28th Annual Milken Institute Global Conference - Bluefield Daily Telegraph
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Cboe Canada Single Security - Cboe Global Markets
Cybin advances Phase 3 trial for depression treatment By Investing.com - Investing.com South Africa
Cybin Announces Additional Strategic Clinical Site Partnerships - GuruFocus
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Prog - GuruFocus
Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials - TipRanks
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Program | CYBN Stock News - GuruFocus
Cybin advances Phase 3 trial for depression treatment - Investing.com
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025 - marketscreener.com
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire
(CYBN) Trading Report - news.stocktradersdaily.com
Cybin (CYBN) Partners with Osmind for Psychedelic Therapy Launch - GuruFocus
Psychedelic drug developer Cybin partners with Osmind (CYBN:NYSE) - Seeking Alpha
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - 01net
Cybin Partners With Osmind to Support Psychiatry Program Pipeline - marketscreener.com
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs | CYBN Stock News - GuruFocus
Cybin's Game-Changing Mental Health Partnership: 800+ Clinics to Deploy Novel Depression and Anxiety Treatments - Stock Titan
Where are the Opportunities in (CYBN) - news.stocktradersdaily.com
Filament Health secures investment to remedy concerning financial position - Mugglehead Magazine
4 Psychedelic Stocks to Buy Now - The Motley Fool
CYBN Stock Forecast: Projections From 2025 To 2040 - Exla Resources
Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th - Business Wire
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited - MSN
(CYBN) Investment Analysis and Advice - news.stocktradersdaily.com
Guggenheim Initiates Coverage of Cybin (CYBN) with Buy Recommendation - Nasdaq
Cybin initiated with a Buy at Guggenheim - TipRanks
Cybin Inc. Reports Q3 2025 Financial Results and Strategic Progress - TipRanks
Psychedelic Science 2025 Announces Select Speakers for the Leading Conference on Psychedelic Research, Policy, and Thought Leadership - GlobeNewswire Inc.
Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq
Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet - MSN
Cybin (OTCMKTS:CLXPF) Shares Down 2.5%Here's What Happened - MarketBeat
How to Take Advantage of moves in (CYBN) - news.stocktradersdaily.com
Revolutionizing Mental Health Through Psychedelic Therapeutics | by Dr. Gleb Tsipursky | Feb, 2025 - DataDrivenInvestor
Cybin (NYSE:CYBN) Price Target Cut to $150.00 by Analysts at HC Wainwright - MarketBeat
Cybin (OTCMKTS:CYBN) Trading Up 1.2%Here's Why - MarketBeat
Canaccord cuts Cybin stock target to $73, maintains Buy rating - MSN
Cybin (NYSE:CYBN) Price Target Lowered to $73.00 at Canaccord Genuity Group - MarketBeat
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin Inc (CYBN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):